Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,026
archived clinical trials in
Epilepsy

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated:  12/31/1969
Investigator Site 102
mi
from
Brno,
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy
Status: Enrolling
Updated: 12/31/1969
Investigator Site 102
mi
from
Brno,
Click here to add this to my saved trials
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Minneapolis, MN
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wellington, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wellington, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hammond, LA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hammond, LA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waldorf, MD
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waldorf, MD
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Golden Valley, MN
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Springfield, MO
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Missoula, MT
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Camden, NJ
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Camden, NJ
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greensboro, NC
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Canton, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Madison, WI
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange, CA
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Akron, OH
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated:  12/31/1969
104
mi
from
Chatswood,
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Status: Enrolling
Updated: 12/31/1969
104
mi
from
Chatswood,
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Durham, NC
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Gulf Breeze, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Port Charlotte, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wellington, FL
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wellington, FL
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Paul, MN
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Study in Pediatric Subjects With Epilepsy
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Buspirone Therapy for Localized Epilepsy
A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Buspirone Therapy for Localized Epilepsy
A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Akron, OH
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials